Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2025-01-23 00:00:00 ET · period of report 2025-01-21 · accession 0000950170-25-008451 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2025-01-23 | 2025-01-21+ | RLAY | Patel Sanjiv | Pres, CEO, Dir | S - Sale | $4.70 | -375.0K | 199.5K | -65% | -$1.76M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-21 | S | D | 125,000 | $4.52 | 449,548 | I By The Patel Family Irrevocable Trust of 2019 | — | — | (F1) These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. (F2) This transaction was executed in multiple trades at prices ranging from $4.35 to $4.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| 2 | Common | Common Stock | 2025-01-22 | S | D | 125,000 | $4.80 | 324,548 | I By The Patel Family Irrevocable Trust of 2019 | — | — | (F1) These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. (F4) This transaction was executed in multiple trades at prices ranging from $4.65 to $4.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| 3 | Common | Common Stock | 2025-01-23 | S | D | 125,000 | $4.78 | 199,548 | I By The Patel Family Irrevocable Trust of 2019 | — | — | (F1) These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. (F5) This transaction was executed in multiple trades at prices ranging from $4.62 to $4.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |